New Delhi, Animal healthcare solutions provider Ajooni Biotech is expecting additional annual revenue of Rs 200 crore from commercial production of moringa by financial year 2025-26.
The leading animal feed manufacturer on Monday revealed its plans for commercial production of Moringa by financial year 2025-26.
“We anticipate generating significant additional annual revenue of Rs 15 crore to Rs 200 crore from our moringa operations with an estimated profit margin of 40-50 per cent by FY2026,” he said.
Moringa provides important benefits for animal welfare and Moringa oil, obtained from the seeds, displays promising characteristics for use in aviateo biofuels.
Recognizing this potential, Ajooni Biotech is actively integrating Moringa into its product development strategy, the statement said.Jasjot Singh, Managing Director, Ajooni Biotech, said, “The Moringa revolution is upon us, and Ajooni Biotech is at the forefront. Moringa, often called the ‘miracle tree’, holds immense potential for the future of animal health and sustainable practices. "
Meanwhile, Ajooni Biotech aims to raise Rs 43.81 crore from the ongoing rights-issue, which opened on May 21 and will close on May 31.
Shareholders have the opportunity to acquire additional shares at a discounted price of Rs 5 per share – a discount of more than 20 per cent on the closing share price on March 18, 2024.
The funds raised through the rights issue will be helpful in moving towards our goal of starting commercial production of Moringa by FY 2026, Singh said.Singh said, “This focus positions Ajooni Biotech to capture a significant share of the market for natural and sustainable animal health care solutions. We have leased 64,000 square yards of land in Derabassi, Punjab for moring nursery and plantation. Have taken."
The company said Ajooni Biotech's rights issue marks a strategic step towards unlocking the huge potential of Moringa in the animal healthcare market, creating a sustainable and profitable future for Ajooni and its stakeholders.
Looking to the future, Ajooni Biotech has partnered with Unnati Agri-Allied and Marketin Multi State Cooperative Society Limited (UAMMCL), a consortium led by the Department of Biotechnology (Government of India) and Punjab, to revolutionize pure-vegetarian animal feed and moringa production. Supported by the State Council for Science Technology. ,
The company has received an export order from Avon Animal Health, Bangladesh to distribute animal health products and educate farmers about their effectiveness.Additionally, the company is working on expanding into the business-to-consumer (B2C) market by appointing more than 100 dealers across India.
It plans to cross 300 distribution touch points and aims to strengthen its market presence and offer innovative products directly to consumers.
In FY24, Ajooni Biotech's net profit increased by 93.75 per cent to Rs 2.1 crore.
The leading animal feed manufacturer on Monday revealed its plans for commercial production of Moringa by financial year 2025-26.
“We anticipate generating significant additional annual revenue of Rs 15 crore to Rs 200 crore from our moringa operations with an estimated profit margin of 40-50 per cent by FY2026,” he said.
Moringa provides important benefits for animal welfare and Moringa oil, obtained from the seeds, displays promising characteristics for use in aviateo biofuels.
Recognizing this potential, Ajooni Biotech is actively integrating Moringa into its product development strategy, the statement said.Jasjot Singh, Managing Director, Ajooni Biotech, said, “The Moringa revolution is upon us, and Ajooni Biotech is at the forefront. Moringa, often called the ‘miracle tree’, holds immense potential for the future of animal health and sustainable practices. "
Meanwhile, Ajooni Biotech aims to raise Rs 43.81 crore from the ongoing rights-issue, which opened on May 21 and will close on May 31.
Shareholders have the opportunity to acquire additional shares at a discounted price of Rs 5 per share – a discount of more than 20 per cent on the closing share price on March 18, 2024.
The funds raised through the rights issue will be helpful in moving towards our goal of starting commercial production of Moringa by FY 2026, Singh said.Singh said, “This focus positions Ajooni Biotech to capture a significant share of the market for natural and sustainable animal health care solutions. We have leased 64,000 square yards of land in Derabassi, Punjab for moring nursery and plantation. Have taken."
The company said Ajooni Biotech's rights issue marks a strategic step towards unlocking the huge potential of Moringa in the animal healthcare market, creating a sustainable and profitable future for Ajooni and its stakeholders.
Looking to the future, Ajooni Biotech has partnered with Unnati Agri-Allied and Marketin Multi State Cooperative Society Limited (UAMMCL), a consortium led by the Department of Biotechnology (Government of India) and Punjab, to revolutionize pure-vegetarian animal feed and moringa production. Supported by the State Council for Science Technology. ,
The company has received an export order from Avon Animal Health, Bangladesh to distribute animal health products and educate farmers about their effectiveness.Additionally, the company is working on expanding into the business-to-consumer (B2C) market by appointing more than 100 dealers across India.
It plans to cross 300 distribution touch points and aims to strengthen its market presence and offer innovative products directly to consumers.
In FY24, Ajooni Biotech's net profit increased by 93.75 per cent to Rs 2.1 crore.
